Proposed new alley causes rift in New Castle
Members of the New Castle Planning Commission want businesses along East Washington Street to get along with one another.
Stay updated with breaking news from Debbie Baron. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Members of the New Castle Planning Commission want businesses along East Washington Street to get along with one another.
A CARE home resident celebrated her 95th birthday in style thanks to kind-hearted staff who fulfilled her special wish.
Updated 2/17/2021 6:56 PM Despite a recommendation from district administrators to hire a firm to better address the needs of an increasingly diverse student population, the St. Charles Unit District 303 school board continues to debate the subject and hear from the community on both sides of the issue. At Tuesday's learning and teaching committee meeting, the board listened to a presentation from representatives of Deep Equity, a company that trains school staff on equity, diversity and inclusion. Deep Equity -- which also has worked with Batavia High School, Elgin Area School District U-46 ...
Pfizer is investing US$25m in a US developer of live biotherapeutics, Vedanta Biosciences; that project is one of four investments, totaling US$120m, made by Pfizer in the second half of 2020 under its breakthrough growth program focused on clinical stage biotech companies of potential future strategic interest to the pharma giant.
These updates are republished press releases and communications from members of the Science|Business Network Pfizer invests $120M in four biotechnological innovation companies Pfizer Inc. today announced that, during the second half of 2020, it invested a total of $120 million in four clinical-stage biotech companies as part of the Pfizer Breakthrough Growth Initiative (PBGI). Through PBGI, Pfizer is investing up to $500 million in biotechnology companies, providing funding and access to Pfizer’s scientific expertise to help ensure the continuity of promising clinical development programs...